Pharmaceutical co-crystals of posaconazole for improvement of physicochemical properties
DOI:
https://doi.org/10.1590/s2175-97902022e191024Keywords:
Co-crystal, Dissolution, Posaconazole, Adipic acidAbstract
Posaconazole exerts an extended spectrum of antifungal activity against various strains of clinically relevant moulds and yeasts. In recent years, antifungal triazole posaconazole has become increasingly important for the prophylaxis and treatment of systemic mycoses. After oral administration of posaconazole, absolute bioavailability has been estimated to range from 8% to 47%. Pharmaceutical co-crystallization is a promising approach for improving dissolution rate or manipulating other physical properties of API. The objective of this study is to improve the dissolution rate of posaconazole by co-crystallization. A 1:1 stoichiometric co-crystals of adipic acid were prepared by solvent assisted grinding method. The prepared co-crystals were subjected to solid-state characterization by FTIR, PXRD and DSC studies. The physicochemical properties of posaconazole and co-crystals were assessed in terms of melting point, flowability and dissolution rate. The results indicated improvement in flow property and dissolution rate. In vitro dissolution profile of co-crystals showed a significant increased dissolution of posaconazole from initial period in 0.1 N hydrochloric acid solution. The dissolution efficiency for posaconazole-adipic acid co-crystal was 61.65 % against posaconazole, 46.58 %. Thus, co-crystallization can be a promising approach to prepare posaconazole-adipic acid co-crystals with improved physicochemical properties.
Downloads
References
Amidon GL, Higuchi W, Ho NF. Theoretical and experimental studies of transport of micelle-solubilized solutes. J Pharm Sci. 1982;71(1):77-84.
Amidon GL, Lennernäs H, Shah VP, Crison JRA .Theoretical basis for a biopharmaceutic drug classification: The correlation of in Vitro drug product dissolution and in Vivo bioavailability. Pharm Res. 1995;12(3):413−420.
Benet L, Broccatelli F, Oprea T. BDDCS applied to over 900 drugs. AAPS J. 2011;13(4):519-547.
Buckton G. Solid state properties, in: Aulton ME (Ed.), Pharmaceutics: The science of dosage form, Churchill Livingstone, 1998.
Cheney M, Weyna DR, Shan N, Hanna M, Wojtas L, Zaworotko MJ. Coformer selection in pharmaceutical co-crystal development: A case study of a meloxicam aspirin co-crystal that exhibits enhanced solubility and pharmacokinetics. J Pharm Sci . 2011;100(6):2172-2181.
Cheney ML, Weyna DR, Shan N, Hanna M, Wojtas L, Zaworotko MJ. Supramolecular architectures of meloxicam carboxylic acid co-crystals, a crystal engineering case study. Cryst Growth Des. 2010;10(10):4401-4413.
Connolly P, Wheat J, Schnizlein-Bick C, Durkin M, Kohler S, Smedema M et al. Comparison of a new triazole antifungal agent, schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob Agents Chemother. 1999;43(2):322-328.
Costa P, Sousa lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci . 2001;13:123-133.
Cristofoletti R, Patel N, Dressman JB. Differences in food effects for 2 weak bases with similar BCS drug-related properties: What Is happening in the intestinal lumen? J Pharm Sci . 2016;105(9):2712−2722.
Desiraju G. Supramolecular Synthons in Crystal Engineering-A New organic synthesis. Angew Chem Int Edition in English. 1995;34(21):2311-2327.
Etter M. Encoding and decoding hydrogen-bond patterns of organic compounds. Acc Chem Res. 1990;23(4):120-126.
Gadade D, Pekamwar S, Lahoti S, Patni S, Sarode M. Co-crystallization of Etodolac: Prediction of co-crystallization, synthesis, solid state characterization and in vitro drug release. Marmara Pharm J. 2017;21:78-88.
Garekani HA, Sadeghi F, Badiee A, Mostafa SA, Rajab-Siahboomi AR. Crystal habit modifications of ibuprofen and their physicochemical characteristics. Drug Dev Ind Pharm. 2001;803-809.
Karagianni A, Malamatari M, Kachrimanis K. Pharmaceutical Cocrystals: New solid phase modification approaches for the formulation of APIs. Pharmaceutics. 2018;10(1)18.
Kuminek G, Cavanagh KL, M.da Piedade MF, Hornedo NR. Posaconazole cocrystal with superior solubility and dissolution behavior. Cryst Growth Des . 2019;19:6592−6602.
Lee H, Zhang G, Flanagan D. Cocrystal intrinsic dissolution behavior using a rotating disk. J Pharm Sci . 2011;100(5):1736-1744.
Long B, Verma V, Ryan KM, Padrela L. Generation and physicochemical characterization of posaconazole cocrystals using Gas Antisolvent (GAS) and Supercritical Solvent (CSS) methods. J Supercrit Fluid. 2020 (in press).
Mohammad M, Alhalaweh A, Velaga S. Hansen solubility parameter as a tool to predict cocrystal formation. Int J Pharm. 2011;407(1-2):63-71.
Mulye SP, Jamadarv SA, Karekar PS, Pore YV, Dhawale SC. Improvement in physicochemical properties of ezetimibe using a crystal engineering technique. Powder Technol. 2012;222:131-138.
Mutalik S, Manoj K, Reddy MS, Kushtagi P, Nayak Usha V, Parambil A et al. Chitosan and enteric polymer based once daily sustained release tablets of aceclofenac: In vitro and in vivo studies AAPS Pharm Sci Tech. 2008;9(2):651-659.
Nijhawan M, Santhosh A, PR Sathesh Babu, Subrahmanyam CVS. Solid state manipulation of lornoxicam for cocrystals- physicochemical characterization. Drug Dev Ind Pharm . 2014;40(9):1163-1172.
Patric JS. Martin’s physical pharmacy and pharmaceutical sciences. 6th edition. USA: Lippincott Williams and Wilkins. 2011;556-558.
Rahman Z, Samy R, Sayeed V, Khan M. Physicochemical and mechanical properties of carbamazepine co-crystals with saccharin. Pharm Dev Technol. 2011;17(4):457-465.
Ross S, Lamprou D, Douroumis D. ChemInform Abstract: Engineering and manufacturing of pharmaceutical co-crystals: A review of solvent-free manufacturing technologies. ChemInform. 2016;47(37).
Schiller D, Fung H. Posaconazole: An extended-spectrum triazole antifungal agent. Clin Ther. 2007;29(9):1862-1886.
Schultheiss N, Newman A. Pharmaceutical Cocrystals and Their Physicochemical Properties. Cryst Growth Des . 2009;9(6)2950-2967.
Stanton MK, Bak A. Physicochemical properties of pharmaceutical co-crystals: A case study of ten AMG 517 co-crystals. Cryst Growth Des . 2008;8:3856-3862.
Tsutsumi S, Lida M, Tada N, Kojima T, Ikeda Y. Characterization and evaluation of miconazole salts and co-crystals for improved physicochemical properties. Int J Pharm . 2011;421:230-236.
Walravens J, Brouwers J, Spriet I, Tack J. Annaert P, Augustijns P. Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations. Clin Pharmacokinet. 2011;50(11):725−34.
Weyna D, Shattock T, Vishweshwar P, Zaworotko M. Synthesis and structural characterization of cocrystals and Pharmaceutical Cocrystals: Mechanochemistry vs slow evaporation from solution. Cryst Growt. Des. 2009;9(2):1106-1123.
Yadav AV, Dabke AP, Shete AS. Crystal engineering to improve physicochemical properties of mefloquine hydrochloride. Drug Dev Ind Pharm . 2010;36(9):1036-1045.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
